Oral Retinoids: Isotretinoin Prescribing and iPLEDGE

Isotretinoin is a powerful oral retinoid primarily used for the treatment of severe acne vulgaris. Due to its teratogenic effects, the iPLEDGE program is mandated to ensure safe prescribing and patient compliance in preventing fetal exposure.

Topics: isotretinoin, retinoids, acne

Overview / Definition Isotretinoin (13-cis-retinoic acid) is a systemic retinoid derived from vitamin A, primarily indicated for the treatment of severe cystic acne that has not responded to conventional therapies. It is known for its efficacy in reducing sebaceous gland activity and promoting skin turnover. Epidemiology Acne vulgaris affects approximately 85% of adolescents and young adults, with a significant percentage progressing to severe forms requiring treatment with isotretinoin. The drug is most commonly prescribed to patients aged 12 to 25 years, though it can be used in older populations. Pathophysiology / Mechanism Isotretinoin exerts its effects through multiple mechanisms: Reduction of sebum production: It decreases the size and activity of sebaceous glands. Alteration of keratinization: It normalizes the shedding of skin cells and reduces follicular plugging. Anti-inflammatory effects: It reduces the inflammatory response associated with acne lesions. Antibacterial properties: It decreases the population of Propionibacterium acnes on the skin. Clinical Presentation Patients requiring isotretinoin typically present with: Severe, nodular, or cystic acne Persistent acne despite the use of topical and systemic antibiotics Persistent scarring or psychosocial distress from acne Diagnosis / Workup The diagnosis of severe acne is clinical and involves: Dermatological examination to assess the severity and type of acne lesions. Laboratory tests to evaluate liver function and lipid levels prior to initiation and during therapy. Pregnancy testing for female patients of childbearing age to rule out pregnancy. Treatment / Management Before starting isotretinoin, it is crucial to enroll the patient in the iPLEDGE program, which is designed to prevent fetal exposure to the medication. The management steps include: Obtain informed consent explaining the risks, benefits, and potential side effects. Initiate isotretinoin therapy at a typical dose of 0.5 to 1.0 mg/kg/da